002393 力生制药
已收盘 07-08 15:00:00
资讯
新帖
简况
力生制药:降本增效已取得阶段性成果
证券之星 · 07-03
力生制药:降本增效已取得阶段性成果
力生制药:松树牌人参补丸为OTC中成药
证券之星 · 06-26
力生制药:松树牌人参补丸为OTC中成药
力生制药(002393)披露使用闲置募集资金进行现金管理的进展公告,6月25日股价下跌2.71%
证券之星 · 06-25
力生制药(002393)披露使用闲置募集资金进行现金管理的进展公告,6月25日股价下跌2.71%
力生制药(002393)披露2026年第二次临时股东会决议公告,6月24日股价上涨1.3%
证券之星 · 06-24
力生制药(002393)披露2026年第二次临时股东会决议公告,6月24日股价上涨1.3%
力生制药(002393)披露药品格列吡嗪控释片通过上市许可申请公告,6月16日股价上涨1.46%
证券之星 · 06-16
力生制药(002393)披露药品格列吡嗪控释片通过上市许可申请公告,6月16日股价上涨1.46%
力生制药最新公告:格列吡嗪控释片通过上市许可申请
证券之星 · 06-15
力生制药最新公告:格列吡嗪控释片通过上市许可申请
力生制药:公司为地方国有控股上市公司
证券之星 · 06-04
力生制药:公司为地方国有控股上市公司
股市必读:力生制药(002393)5月25日董秘有最新回复
证券之星 · 05-26
股市必读:力生制药(002393)5月25日董秘有最新回复
股市必读:力生制药(002393)5月21日董秘有最新回复
证券之星 · 05-22
股市必读:力生制药(002393)5月21日董秘有最新回复
力生制药:近年在仿制药一致性评价等方面取得多项阶段性落地成果
证券之星 · 05-21
力生制药:近年在仿制药一致性评价等方面取得多项阶段性落地成果
股市必读:力生制药(002393)5月20日董秘有最新回复
证券之星 · 05-21
股市必读:力生制药(002393)5月20日董秘有最新回复
力生制药:高管薪酬正常浮动,并非降薪
证券之星 · 05-14
力生制药:高管薪酬正常浮动,并非降薪
力生制药(002393)披露高级管理人员减持股份预披露公告,5月8日股价下跌0.54%
证券之星 · 05-08
力生制药(002393)披露高级管理人员减持股份预披露公告,5月8日股价下跌0.54%
力生制药:使用闲置自有资金进行现金管理
证券之星 · 05-08
力生制药:使用闲置自有资金进行现金管理
力生制药:研发费用比上年同期减少35.03%
证券之星 · 04-27
力生制药:研发费用比上年同期减少35.03%
股市必读:力生制药(002393)4月24日收盘跌5.14%,主力净流入432.57万元
证券之星 · 04-27
股市必读:力生制药(002393)4月24日收盘跌5.14%,主力净流入432.57万元
力生制药(002393)2026年一季报简析:净利润同比下降6.14%
证券之星 · 04-25
力生制药(002393)2026年一季报简析:净利润同比下降6.14%
力生制药(002393)披露2026年一季度报告,4月23日股价下跌1.83%
中金财经 · 04-24
力生制药(002393)披露2026年一季度报告,4月23日股价下跌1.83%
天津发展(00882):力生制药一季度归母净利润约5188.3万元,同比减少6.14%
智通财经 · 04-24
天津发展(00882):力生制药一季度归母净利润约5188.3万元,同比减少6.14%
力生制药季度归属股东净利润达5188万元
美股速递 · 04-24
力生制药季度归属股东净利润达5188万元
加载更多
公司概况
公司名称:
天津力生制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-04-23
主营业务:
天津力生制药股份有限公司的主营业务是医药产品研发、生产和销售。公司的主要产品是寿比山吲达帕胺片、三鱼氨酚咖匹林片、希福尼头孢地尼分散片、友好麻仁软胶囊、生化氢化可的松琥珀酸钠冻干粉针和碳酸氢钠片、盖胃平片、麻仁润肠丸、虎力散片。公司坚持以科技创新赋能产业高质量发展,创新能力和可持续发展能力持续增强,产品包括心脑血管、消化、抗感染、呼吸、跌打等15大类297个药品,拥有注册商标189个。
发行价格:
45.00
{"stockData":{"symbol":"002393","market":"SZ","secType":"STK","nameCN":"力生制药","latestPrice":14.62,"timestamp":1783494186000,"preClose":14.53,"halted":0,"volume":2542717,"delay":0,"changeRate":0.0062,"floatShares":300000000,"shares":309000000,"eps":1.3364,"marketStatus":"已收盘","change":0.09,"latestTime":"07-08 15:00:00","open":14.54,"high":14.86,"low":14.35,"amount":37189500,"amplitude":0.0351,"askPrice":14.62,"askSize":74,"bidPrice":14.6,"bidSize":32,"shortable":0,"etf":0,"ttmEps":1.3364,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783560600000},"marketStatusCode":5,"adr":0,"adjPreClose":14.53,"symbolType":"stock","openAndCloseTimeList":[[1783474200000,1783481400000],[1783486800000,1783494000000]],"highLimit":15.98,"lowLimit":13.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":308964215,"isCdr":false,"pbRate":0.97,"roa":"--","peRate":10.939838,"roe":"1.12%","epsLYR":1.62,"committee":-0.40412,"marketValue":4517000000,"turnoverRate":0.0085,"status":0,"floatMarketCap":4389000000},"requestUrl":"/m/hq/s/002393","defaultTab":"news","newsList":[{"id":"2648634526","title":"力生制药:降本增效已取得阶段性成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634526?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:43","pubTimestamp":1783039387,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药07月02日在投资者关系平台上答复投资者关心的问题。力生制药回复:尊敬的投资者您好,公司董事会统筹健全\"1+N\"价值沟通管理体系,优化投资者回报机制,兼顾股东短期回报与长期价值增长。在经营层面,公司持续压实主业基本面,加快产品结构优化与降本增效。2026年一季报,降本增效已取得阶段性成果,费用管控效果明显。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646233303","title":"力生制药:松树牌人参补丸为OTC中成药","url":"https://stock-news.laohu8.com/highlight/detail?id=2646233303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646233303?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:34","pubTimestamp":1782444855,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药(002393)06月26日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好:旗下药企的“松树”牌人参补丸,电商平台都搜不到,请问您在哪里能够买到?力生制药回复:投资者您好,感谢您关注公司及旗下中央药业松树牌人参补丸产品,本品为OTC中成药,公司现阶段核心销售渠道聚焦实体医药终端,2026 年产品完成包装焕新后,全国铺货持续推进中,您可关注“力生制药”官方公众号或致电022-27641760,感谢您的关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600018245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","002393","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646016138","title":"力生制药(002393)披露使用闲置募集资金进行现金管理的进展公告,6月25日股价下跌2.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646016138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646016138?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:57","pubTimestamp":1782399435,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘,力生制药报收于14.35元,较前一交易日下跌2.71%,最新总市值为44.34亿元。近日,天津力生制药股份有限公司发布《关于使用闲置募集资金进行现金管理的进展公告》。公告显示,公司于2026年6月25日使用闲置募集资金13,000万元在兴业银行购买结构性存款,其中12,000万元期限约172天,预计年化收益率1.00%-1.60%。截至公告日,未到期理财金额为20,000万元,未超出股东大会审批额度。公司已采取多项风险控制措施,确保资金安全。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002393","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645981943","title":"力生制药(002393)披露2026年第二次临时股东会决议公告,6月24日股价上涨1.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645981943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645981943?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:27","pubTimestamp":1782311235,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘,力生制药报收于14.75元,较前一交易日上涨1.3%,最新总市值为45.57亿元。该股当日开盘14.52元,最高14.89元,最低14.43元,成交额达5668.53万元,换手率为1.28%。近日,天津力生制药股份有限公司发布《2026年第二次临时股东会决议公告》。其中前两项提案为特别决议事项,均已获出席会议有表决权股东所持股份的三分之二以上通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400044035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002393","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643554707","title":"力生制药(002393)披露药品格列吡嗪控释片通过上市许可申请公告,6月16日股价上涨1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643554707","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643554707?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:18","pubTimestamp":1781605096,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘,力生制药报收于14.58元,较前一交易日上涨1.46%,最新总市值为45.05亿元。该股当日开盘14.4元,最高14.93元,最低14.4元,成交额达5117.94万元,换手率为1.17%。力生制药于近日披露《关于药品格列吡嗪控释片通过上市许可申请的公告》。公告显示,公司收到国家药品监督管理局颁发的《药品注册证书》,格列吡嗪控释片5mg规格通过上市许可申请。此次获批将丰富公司内分泌系统药物产品线,提升市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600033446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643792272","title":"力生制药最新公告:格列吡嗪控释片通过上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2643792272","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643792272?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:54","pubTimestamp":1781513694,"startTime":"0","endTime":"0","summary":"力生制药(002393.SZ)公告称,公司收到国家药品监督管理局颁发的关于格列吡嗪控释片5mg规格的《药品注册证书》,该药品通过上市许可申请,适用于改善2型糖尿病成人患者的血糖控制。此举将进一步丰富公司内分泌系统药物产品线,提高市场竞争力。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500020636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640990137","title":"力生制药:公司为地方国有控股上市公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2640990137","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640990137?lang=zh_cn&edition=full","pubTime":"2026-06-04 15:01","pubTimestamp":1780556468,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药06月04日在投资者关系平台上答复投资者关心的问题。国家对国企上市公司破净管理考核对贵司有效吗?此外,公司将深化市值管理战略谋划,统筹健全价值沟通管理体系,优化投资者回报机制,推动内在价值与市场价值协同提升。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400020428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638855457","title":"股市必读:力生制药(002393)5月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638855457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638855457?lang=zh_cn&edition=full","pubTime":"2026-05-26 02:02","pubTimestamp":1779732142,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘,力生制药报收于15.07元,下跌0.72%,换手率0.73%,成交量2.2万手,成交额3307.69万元。董秘最新回复投资者: 接苹果手机案例,可以看出,如果自己的产业链某个环节出问题或者唯一供应商出问题,对企业生产都会造成重大影响。当日关注点来自交易信息汇总:5月25日主力资金净流出499.62万元,散户资金净流入483.55万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600001486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637359010","title":"股市必读:力生制药(002393)5月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637359010","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637359010?lang=zh_cn&edition=full","pubTime":"2026-05-22 03:38","pubTimestamp":1779392293,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘,力生制药报收于15.05元,下跌2.46%,换手率0.85%,成交量2.55万手,成交额3909.69万元。董秘最新回复投资者: 您好堇秘,贵司的研发费用不少,但和研发成果不必比例,难道就没有一个项目研发成功吗?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200005063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637805799","title":"力生制药:近年在仿制药一致性评价等方面取得多项阶段性落地成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2637805799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637805799?lang=zh_cn&edition=full","pubTime":"2026-05-21 11:36","pubTimestamp":1779334585,"startTime":"0","endTime":"0","summary":"回顾近年度,公司在仿制药一致性评价、制剂工艺优化、现有产品质量提升、配套原料药技术改良等方面均取得多项阶段性落地成果,部分改良剂型、优化工艺品种已顺利完成相关审评备案与投产落地并对外披露,持续丰富现有产品矩阵、稳固市场供货能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100018946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","002393","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637820676","title":"股市必读:力生制药(002393)5月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637820676","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637820676?lang=zh_cn&edition=full","pubTime":"2026-05-21 03:33","pubTimestamp":1779305590,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘,力生制药报收于15.43元,下跌1.15%,换手率0.95%,成交量2.85万手,成交额4377.87万元。当日关注点来自交易信息汇总:5月20日主力资金净流出252.96万元,游资资金亦呈净流出态势,散户资金净流入435.27万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100004440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","002393","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635750579","title":"力生制药:高管薪酬正常浮动,并非降薪","url":"https://stock-news.laohu8.com/highlight/detail?id=2635750579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635750579?lang=zh_cn&edition=full","pubTime":"2026-05-14 08:39","pubTimestamp":1778719148,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药05月13日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,看到管理层2025年的工资较2024年的工资降幅比较大,想了解下为啥会降薪这么多?研发、销售核心团队没有集体降薪,基层及业务骨干薪酬整体保持稳定,优秀人员还有绩效激励。公司成本优化主要从管理端精简,同时保障一线员工待遇和团队稳定,维护工作积极性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633843972","title":"力生制药(002393)披露高级管理人员减持股份预披露公告,5月8日股价下跌0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633843972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633843972?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:27","pubTimestamp":1778232446,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,力生制药报收于16.5元,较前一交易日下跌0.54%,最新总市值为50.98亿元。近日,力生制药发布《关于公司高级管理人员减持股份预披露公告》。公告显示,公司高级管理人员郭晓燕女士持有公司股份124,320股,占公司总股本的0.0402%,占剔除回购专用账户后总股本的0.0403%。郭晓燕女士计划在公告披露之日起15个交易日后的3个月内,通过集中竞价方式减持不超过22,042股,占其持股总数的25%,占公司剔除回购专用账户后总股本的0.0072%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800031184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633488468","title":"力生制药:使用闲置自有资金进行现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2633488468","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633488468?lang=zh_cn&edition=full","pubTime":"2026-05-08 11:36","pubTimestamp":1778211395,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药(002393)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,面对持续破净局面,公司以现金理财方式获得的收益vs回购增厚EPS,哪种对股东价值更优?请您务必尽职答复为盼!力生制药回复:投资者您好,公司为提高公司资金使用效率,合理利用自有资金,增加公司收益,在保证公司日常经营资金需求及资金流动性、安全性前提下使用闲置自有资金进行的现金管理。感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800017387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630200356","title":"力生制药:研发费用比上年同期减少35.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630200356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630200356?lang=zh_cn&edition=full","pubTime":"2026-04-27 11:36","pubTimestamp":1777260972,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药04月27日在投资者关系平台上答复投资者关心的问题。研发费用比上年同期减少35.03%,其主要原因:研发项目付款节点不均衡;一季度业绩波动是转型的阶段性表现,公司正通过渠道扩张、新品放量、研发攻坚、资本赋能四维发力,夯实长期增长基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700017707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002393","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630019331","title":"股市必读:力生制药(002393)4月24日收盘跌5.14%,主力净流入432.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630019331","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630019331?lang=zh_cn&edition=full","pubTime":"2026-04-27 06:39","pubTimestamp":1777243149,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,力生制药报收于21.4元,下跌5.14%,换手率2.78%,成交量6.96万手,成交额1.48亿元。当日关注点来自交易信息汇总:力生制药股价连续4日下跌,4月24日收跌5.14%至21.4元,前10个交易日主力资金累计净流出超3593万元。来自业绩披露要点:力生制药2026年一季度主营收入同比下降10.16%,归母净利润同比下降6.14%,扣非净利润降幅扩大至12.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700006736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002393","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630878024","title":"力生制药(002393)2026年一季报简析:净利润同比下降6.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630878024","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630878024?lang=zh_cn&edition=full","pubTime":"2026-04-25 06:23","pubTimestamp":1777069439,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期力生制药发布2026年一季报。根据财报显示,力生制药净利润同比下降6.14%。截至本报告期末,公司营业总收入3.32亿元,同比下降10.16%,归母净利润5188.3万元,同比下降6.14%。然而去年的净利率为30.37%,算上全部成本后,公司产品或服务的附加值极高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500020663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629862056","title":"力生制药(002393)披露2026年一季度报告,4月23日股价下跌1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629862056","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629862056?lang=zh_cn&edition=full","pubTime":"2026-04-24 08:16","pubTimestamp":1776989790,"startTime":"0","endTime":"0","summary":"近日,天津力生制药股份有限公司披露《2026年第一季度报告》。报告显示,报告期内实现营业收入332,282,846.72元,同比下降10.16%;归属于上市公司股东的净利润为51,882,970.53元,同比下降6.14%;扣除非经常性损益后的净利润为46,869,507.40元,同比下降12.08%。总资产为5,533,055,376.69元,较上年度末减少0.92%;归属于上市公司股东的所有者权益为4,605,756,501.87元,较上年度末减少0.48%。经营活动产生的现金流量净额为988,720.31元,同比增长201.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260424/32170281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002393","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629613108","title":"天津发展(00882):力生制药一季度归母净利润约5188.3万元,同比减少6.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629613108","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629613108?lang=zh_cn&edition=full","pubTime":"2026-04-24 06:20","pubTimestamp":1776982841,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天津发展(00882)发布力生制药2026年第一季度业绩,营业收入约3.32亿元,同比减少10.16%;归属于母公司所有者的净利润约5188.3万元,同比减少6.14%;基本每股收益0.2元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002393","00882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192630681","title":"力生制药季度归属股东净利润达5188万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192630681","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192630681?lang=zh_cn&edition=full","pubTime":"2026-04-24 06:12","pubTimestamp":1776982331,"startTime":"0","endTime":"0","summary":"天津发展控股有限公司旗下子公司天津力生制药股份有限公司公布最新季度业绩,归属公司股东的净利润达到5188万元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1232","002393","BK0239","00882","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783549985044,"stockEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0398},{"period":"3month","weight":-0.2355},{"period":"6month","weight":-0.1776},{"period":"1year","weight":-0.0562},{"period":"ytd","weight":-0.1579}],"compareEarnings":[{"period":"1week","weight":-0.0344},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0363},{"period":"1year","weight":0.1354},{"period":"ytd","weight":0.0005}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"天津力生制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26060人(较上一季度增加19.68%)","perCapita":"11520股","listingDate":"2010-04-23","address":"天津市西青区西青经济技术开发区赛达北一道16号","registeredCapital":"30896万元","survey":" 天津力生制药股份有限公司的主营业务是医药产品研发、生产和销售。公司的主要产品是寿比山吲达帕胺片、三鱼氨酚咖匹林片、希福尼头孢地尼分散片、友好麻仁软胶囊、生化氢化可的松琥珀酸钠冻干粉针和碳酸氢钠片、盖胃平片、麻仁润肠丸、虎力散片。公司坚持以科技创新赋能产业高质量发展,创新能力和可持续发展能力持续增强,产品包括心脑血管、消化、抗感染、呼吸、跌打等15大类297个药品,拥有注册商标189个。","listedPrice":45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"力生制药,002393,力生制药股票,力生制药股票老虎,力生制药股票老虎国际,力生制药行情,力生制药股票行情,力生制药股价,力生制药股市,力生制药股票价格,力生制药股票交易,力生制药股票购买,力生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}